Study of Nefecon and Ambrisentan for IgA Nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two medications, Nefecon and Ambrisentan, to see if they can help people with IgA nephropathy, a kidney disease. It may be an option if you have been diagnosed with IgA nephropathy in the last 4 years and have protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgA nephropathy through a kidney biopsy within the last 4 years.
- You are between 18 and 70 years old.
- You have at least 0.5 grams of protein in your urine over 24 hours.
- Your kidney function (eGFR) is 30 or higher, meaning your kidneys are working moderately well.
- You have not had a heart attack, stroke, or serious heart problems in the last 12 weeks.
- You are not pregnant, breastfeeding, or planning to have children during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new medicine called finerenone can help people with IgA nephropathy, a kidney disease. You may be able to join if you are already on blood pressure medications, your kidney function is at a certain level, and you haven't needed immune-suppressing drugs recently.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial is collecting real-world information from people with IgA nephropathy who are taking the medications iptacopan or atrasentan. The goal is to better understand how these treatments work in everyday medical practice.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.